Steven Tong

Great choice for first article for Bluesky ID journal club! #IDSky @nejm.org @clarityinitiative.bsky.social www.nejm.org/doi/abs/10.1...

Latest from CLARITY. Led by @angelahuttner.bsky.social with myself, @gurujosh.bsky.social and Tom Holland. clarityinitiative.org/commentaries... #IDsky #clarity @cmicomms.bsky.social

🔥 Brilliants minds debate oral fosfomycin for complicated UTI including pyelonephritis. With increasing ESBLs, we need options for UTI beyond cystitis. Oral fosfomycin is an appealing option, but is it ok for infection outside the bladder? #pharmacist #pharmacyschool #learnantibiotics #fosfomycin

💡 Take your clinical trial from concept to completion. Learn how to design, conduct and report a clinical trial through expert-led sessions and workshops covering every stage of the clinical trial journey. Register today: https://ow.ly/lStL50Zrgqa

The next Clarity commentary. On the SNAP trial. Neither I nor @gurujosh.bsky.social had anything to do with this commentary (deliberately). Conclusions though are in line with my interpretation of the data. i.e., use cefazolin for MSSA bacteremia. @angelahuttner.bsky.social @cmicomms.bsky.social

🎙️ Just published 'Does oseltamivir harm critically ill patients? The REMAP-CAP results' Hosted by Erin McCreary, PharmD & Josh Davis with invited guests Steve Webb & Steven Tong 🌟 Listen on #Communicable https://ow.ly/pJAO50ZOfK8 or on #Breakpoints https://ow.ly/p8Ti50ZOfK9 #IDSky #ViroSky #flu

📣 New #Communicable / #Breakpoints drops Mon 21 Sep! Erin McCreary, PharmD & Josh Davis are joined by Steve Webb & Steven Tong to discuss REMAP-CAP results suggesting that oseltamivir may harm critically ill patients, while also highlighting the importance and impact of RCTs. #IDSky #ViroSky #flu

IDSA and ESCMID have released Part 1 of new consensus statements for Staphylococcus aureus bacteremia, introducing a risk-based approach to support diagnostic evaluation and more individualized treatment decisions. 📄: https://www.idsociety.org/practice-guideline/staphylococcus-aureus-bacteremia/

Come along. This will be a great course in an amazing location!

📣We rely more & more on #AI for literature review So how did 6 large language models compare to humans when extracting data from #RCTs for a systematic review? Not very well: overall #LLM concordance was 0.58-0.75. #IDSky @steventong.bsky.social @seanong.bsky.social cmi-comms.org/article/S295...

Can Group C/G Streptococcus (Streptococcus dysgalactiae subsp. equisimilis, SDSE) become penicillin resistant? We report a case in an individual on prolonged penicillin prophylaxis. doi.org/10.1128/aac.... @steventong.bsky.social @thedohertyinst.bsky.social 🧵👇

This course will be great! In Malta too - still warm in November. COI: I'm one of the conveners. Join us!

The SNAP Trial Exemplifies What EBM Should Look Like: www.sensible-med.com/p/the-snap-t... #IDSky

The SNAP trial domain on cefazolin vs cloxacillin for MSSA bacteremia is finally published! www.nejm.org/doi/full/10.... Cefazolin is already the new standard! #IDsky #AMSsky

A landmark international clinical trial (SNAP Trial) has identified the optimal antibiotics for golden staph bloodstream infections, a breakthrough that is set to reshape treatment for the life-threatening condition. https://bit.ly/44eY8Kg

In the SNAP trial, cefazolin was noninferior to flucloxacillin or cloxacillin with respect to 90-day mortality in patients with methicillin-susceptible Staphylococcus aureus bacteremia and had fewer nephrotoxic effects. Read the full trial results: https://nej.md/4vL0M6m

🔥Just published 🔥NEJM SNAP RCT In patients with MSSA bacteremia, cefazolin was noninferior to flucloxacillin or cloxacillin with respect to 90-day mortality and was associated with a lower incidence of acute kidney injury. #idsky www.nejm.org/doi/full/10....

Excited 1st SNAP result out @thelancet.com PSSA: Fluclox v BenPen thelancet.com/journals/lancet/article/PIIS0140-6736(26)00761-0/fulltext @nejm.org MSSA: Fluclox v Cefazolin nejm.org/doi/full/10.1056/NEJMoa2506905 Should change practice globally Privilege to help deliver trial with fantastic team

Great post @apsmunro.bsky.social! Doing more is such a natural reaction. But even 'benign' interventions may likely be harmful when tested properly. I'm yet to know of a trial for sepsis where adding antibiotics has been beneficial (outside of TB where we do it to prevent emergence of resistance).

Honored to contribute to this peer-reviewed commentary in CMI Communications alongside an incredible panel of ID physicians and clinical trialists discussing some of the top infectious diseases papers of 2025. #idsky www.cmi-comms.org/article/S295...

This is a really helpful graphic summary of the Andes virus outbreak. #IDSky

ESCMID 2026 highlights Dalbavancin PK (DOTS‑PK) – Two doses may not be enough High protein binding and wide inter‑patient variability: 1/3 patients may be sub‑therapeutic by day 22 Bottom line: Consider monitoring levels or adding a third dose in complex infections clarityinitiative.org/home

So good. Have spent years fighting this fight, with hand tied behind my back by lack of great evidence. This study is going to get quoted and cited in microbiology MDTs the world over +++ #IDSky #ClinMicro #AMR

ESCMID 2026 highlights COBRA Trial – One day is enough Dutch RCT: 1 day of antibiotics after ERCP drainage for cholangitis was non‑inferior to 4–7 days. Bottom line: Antibiotic durations can safely be much shorter once source control is achieved. #IDSky clarityinitiative.org/escmid-2026-...

Highlights from ESCMID Global 2026? @gurujosh.bsky.social asked CLARITY faculty: @angelahuttner.bsky.social @erinmccreary.bsky.social @marcbonten.bsky.social @seanong.bsky.social @ashabowen.bsky.social and others (not on BlueSky). #IDSky clarityinitiative.org/escmid-2026-... Any that we missed?

Our collaboration episode with Breakpoints covering the trials from the ESCMID Global session 'The trial run' is out now! share.transistor.fm/s/e2a9aee4 🎙️✨ @erinmccreary.bsky.social @gurujosh.bsky.social @jesusrbano.bsky.social #IDSky #clinmicro

Long awaited! 🆕💥🟢REMAP-CAP For critically and noncritically ill hospitalized patients with COVID-19, ivermectin was unlikely to improve the primary composite outcome of organ support-free days and hospital survival #idsky journals.lww.com/ccmjournal/f...

We looked at empiric B-lactam antibiotics in MRSA bacteraemia and BC persistence and AKI, using CAMERA2 dataset. Groups: none, early (only empiric B-lactam), late (only after trial enrolment), throughout (empiric and after enrolment). #IDSky www.clinicalmicrobiologyandinfection.org/article/S119...

Time for societies to incorporate humility of uncertainty into guidelines Evidence Over Eminence: Rethinking Specialty Guidelines Amid the ATS-IDSA Debate academic.oup.com/cid/article/...

🔥 Late Breakers SNAP platform RCT| Adjunctive Clindamycin in S.aureus bacteraemia ❌ No mortality benefit 90d mortality:16.9% vs 15.2% aOR 1.16 (CrI cross 1) 📊PPSup(~7%)→Futility threshold reached ⚠️ICU subgp:numerically worse with clinda ⚖️CDAD:no # (~2%)😯 #ESCMIDGlobal2026 #idsky

📣 New CLARITY articles by Erin McCreary, PharmD & Ahmad Mourad are out to help us understand the GAMECHANGER trial & #cefiderocol The first notes a mortality signal among metallo-β-lactamase–producing infections... #IDSky #clinmicro https://ow.ly/GAqx50Yq6uh

And @gurujosh.bsky.social and I just recorded a podcast with Scott Berry for 'In the Interim'. We discuss the SNAP journey so far. www.berryconsultants.com/resources/po.... Episode should drop in 2-3 weeks. Will post again when it does. @thedohertyinst.bsky.social #IDSky

Just woke up and checked emails to see that 8 new participants recruited to #SNAP_Trial in the past 8 hours! While a number of domains have closed (PSSA, MSSA, adjunctive clindamycin) we continue to recruit to other domains. Beyond 5,800 total participants now. @gurujosh.bsky.social

We were absolutely the beneficiaries of your visit @angelahuttner.bsky.social! We learnt so much about scientific communication and publishing, gender equity in medicine and science, and UTIs! (each was the focus of a talk / discussion Angela led). #IDSky

Awesome to have @angelahuttner.bsky.social visiting in Australia!

With ESCMID Global quickly approaching! To help you spread the word and get involved, check out ESCMID Global 2026 Promotional Toolkit The official hashtag for the congress this year is #ESCMIDGlobal2026 on all social media channels. #IDSky www.escmid.org/congress-eve...

My top 10 ID papers for 2025. Full citations and descriptions available at clarityinitiative.org/hot-takes Also see/hear our Communicable podcast episode on this at communicable.transistor.fm/episodes/com... What were your top 10? Any thoughts about what I missed welcome! #IDSky #Top10papers

Medical research spending has a positive return on investment; for every $ invested there's an estimated $4 return. Beyond economics, delays hold up medical innovations Australians deserve better If you agree, please sign the petition to let #auspol leaders know why medical research matters #NHMRC

🎙️ Just published Communicable E45: Top infectious diseases papers in 2025 Hosted by Josh Davis & Emily McDonald w/ invited guest Steven Tong Listen on #Communicable: https://share.transistor.fm/s/9e626f2a #IDSky #clinmicro

📣 New #Communicable drops Mon 26 Jan! In our last episode, we brought you some favorite #clinmicro papers of 2025. We continue this thread in our next episode with top ID papers of 2025, picked by our editors, Josh Davis & Emily McDonald and guest, Steven Tong. ⭐ Tune in Monday🎙️ #IDSky

💊Drug Hypesensitivity Symposium 2026 - #DHS2026 Registrations are now open for our amazing 3-day #drugallergy & #antibioticallergy program in Melbourne 23-25th October 2026. Stellar international🌏speaker lineup. @allergy-eaaci.bsky.social @thedohertyinst.bsky.social ➡️https://dhs2026.org/

I see patients with TB every week. I can access modern diagnostics and treatments. Reading this book reminded me that is not the case in much of the world. TB kills 1.25 million per year. A disease of injustice. Everything Is Tuberculosis: John Green www.goodreads.com/book/show/22...

Exciting news - there's a spot open in the #IDepi team at @thekidsau.bsky.social ! Prof Chris Blyth is looking for a Research Officer to work on influenza research 1-year initial contract based in Perth Slight bias (my team/boss) but it's a fantastic opportunity! #EpiSky #AcademicSky #AusAcademia

Now I'll have a look at how Covid-19 deaths have changed over time. See the quoted thread for discussion of how cases, emergency department visits, and hospitalizations have changed over time. 1/

Pretty cool that Robin Patel picks Ouli Xie's @lancetmicrobe.bsky.social paper on SDSE and S pyogenes as one of her top 3 clinical microbiology papers for 2025! As expected, Robin does a great job explaining the paper. www.thelancet.com/journals/lan... @onisillos.bsky.social

The 3rd and 4th commentaries on recent ID trials are up on the CLARITY website (we aim to publish in depth reviews of important ID stuies). This time looking at the GAMECHANGER trial: clarityinitiative.org/commentaries... @erinmccreary.bsky.social with Ahmad Mourad @gurujosh.bsky.social #IDSky

The numbers are in. This year's most popular JAMA content spans a range of topics, from coffee and #AFib to #osteoporosis to #SepticShock. What was your favorite article in 2025—and did other readers agree? 🔗 ja.ma/49dIcKr

🆕🔥State of art review article by 🌟 s @drtoddlee.bsky.social @steventong.bsky.social Navigating the Challenges in Staphylococcus aureus Bloodstream Infection: A Practical Guide to Management #idsky #EMIMCC www.sciencedirect.com/science/arti...